A future based on a great foundation

We are building a global leading company that creates long-term value for customers, shareholders, and society at large.

  • 2021

  • Inauguration of Senzime’s manufacturing facility in Uppsala, Sweden.

    Senzimes TetraGraph system and new manufacturing facility certified against MDR.

    Listed on Nasdaq Stockholm’s main market.

    Senzime establishes a subsidiary in Germany, receives first breakthrough order from German university hospital.

 
  • 2020

  • Senzime establishes a subsidiary in the US, Senzime Inc., builds a sales organisation and receives a breakthrough order from a US university hospital.

 
  • 2019

  • Senzime receives marketing approval in the US, Japan and South Korea, allowing it to market and sell its products in these markets.

 
  • 2017

  • Senzime listed on Nasdaq Stockholm First North Growth Market.

 
  • 2016

  • Licensing agreement with Fukuda Denshi in Japan.

    Senzime acquires Acacia Designs B.V. thereby obtaining TetraGraph®, broadening the product range to include solutions for patients undergoing anaesthesia.

 
  • 2015

  • Senzime acquires MD Biomedical AB, the developer of OnZurf®Probe, a new generation of microdialysis catheters.

 
  • 2011

  • Patent obtained for CliniSenz®.

 
  • 2007

  • Senzime is admitted to trading on Aktietorget.

 
  • 2004

  • The first prototype is completed: CliniSenz – a blood glucose analyzer for post-operative and continuous monitoring of patients in a hospital environment.

 
  • 2001

  • The Crafoord family, represented by Adam Dahlberg, invests in the company.

 
  • 1999

  • Senzime is founded with the business idea of developing patient-oriented systems for measuring life-critical substances.

 

Learn more

Do you want to know more?

Contact us for more information.